{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:31:13Z","timestamp":1788985873869,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00192-023-05665-4","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T13:02:56Z","timestamp":1699448576000},"page":"19-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antibiotic prophylaxis for onabotulinum toxin A injections: systematic review and meta-analysis"],"prefix":"10.1007","volume":"35","author":[{"given":"Feven W.","family":"Getaneh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabh","family":"Simhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamir","family":"Sholklapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Melvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Scott","family":"Dorris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiling","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee A.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Dieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"5665_CR1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/nau.22983","volume":"36","author":"P Miotla","year":"2017","unstructured":"Miotla P, Cartwright R, Futyma K, et al. Can Botox improve night-time overactive bladder symptoms in women? Neurourol Urodyn. 2017;36:648\u201352.","journal-title":"Neurourol Urodyn"},{"key":"5665_CR2","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/jama.2016.14617","volume":"316","author":"CL Amundsen","year":"2016","unstructured":"Amundsen CL, Richter HE, Menefee SA, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316:1366\u201374.","journal-title":"JAMA"},{"key":"5665_CR3","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00404-012-2349-8","volume":"286","author":"R Granese","year":"2012","unstructured":"Granese R, Adile G, Gugliotta G, Cucinella G, Saitta S, Adile B. Botox(\u00ae) for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection. Arch Gynecol Obstet. 2012;286:923\u20139.","journal-title":"Arch Gynecol Obstet"},{"key":"5665_CR4","unstructured":"Allergan. Botox (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use. Allergan Database Madison, NJ: Allergan USA; Updated 1 August 2022."},{"key":"5665_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","volume":"367","author":"AG Visco","year":"2012","unstructured":"Visco AG, Brubaker L, Richter HE, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367:1803\u201313.","journal-title":"N Engl J Med"},{"key":"5665_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JU.0000000000000509","volume":"203","author":"DJ Lightner","year":"2020","unstructured":"Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203:351\u20136.","journal-title":"J Urol"},{"key":"5665_CR7","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022;18:e1230.","journal-title":"Campbell Syst Rev"},{"key":"5665_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"5665_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"5665_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/157488709788186021","volume":"4","author":"VW Berger","year":"2009","unstructured":"Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials. 2009;4:79\u201388.","journal-title":"Rev Recent Clin Trials"},{"key":"5665_CR11","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"5665_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jebm.12018","volume":"6","author":"G Goldet","year":"2013","unstructured":"Goldet G, Howick J. Understanding GRADE: an introduction. J Evid Based Med. 2013;6:50\u20134.","journal-title":"J Evid Based Med"},{"key":"5665_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1086\/427507","volume":"40","author":"LE Nicolle","year":"2005","unstructured":"Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643\u201354.","journal-title":"Clin Infect Dis"},{"key":"5665_CR14","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/AOG.0b013e3181a1f5ea","volume":"113","author":"TM Kessler","year":"2009","unstructured":"Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol. 2009;113:1046\u201351.","journal-title":"Obstet Gynecol"},{"key":"5665_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.tcmj.2012.02.002","volume":"24","author":"Q-S Ke","year":"2012","unstructured":"Ke Q-S, Chen Y-C, Kuo H-C. Do baseline urodynamic parameters affect the treatment outcome after intravesical 100 U onabotulinumtoxinA injection in patients with idiopathic detrusor overactivity? Tzu Chi Med J. 2012;24:121\u20136.","journal-title":"Tzu Chi Med J"},{"key":"5665_CR16","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.juro.2008.11.110","volume":"181","author":"S Khan","year":"2009","unstructured":"Khan S, Kessler TM, Apostolidis A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection. J Urol. 2009;181:1773\u20138.","journal-title":"J Urol"},{"key":"5665_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.pharep.2018.08.002","volume":"70","author":"K Juszczak","year":"2018","unstructured":"Juszczak K, Adamczyk P, Maciukiewicz P, Drewa T. Clinical outcomes of intravesical injections of botulinum toxin type A in patients with refractory idiopathic overactive bladder. Pharmacol Rep. 2018;70:1133\u20138.","journal-title":"Pharmacol Rep"},{"key":"5665_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","volume":"123","author":"NA Faure Walker","year":"2019","unstructured":"Faure Walker NA, Syed O, Malde S, Taylor C, Sahai A. Onabotulinum toxin A injections in men with refractory idiopathic detrusor overactivity. Urology. 2019;123:242\u20136.","journal-title":"Urology"},{"key":"5665_CR19","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","volume":"181","author":"MK Flynn","year":"2009","unstructured":"Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181:2608\u201315.","journal-title":"J Urol"},{"key":"5665_CR20","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","volume":"178","author":"HC Kuo","year":"2007","unstructured":"Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol. 2007;178:1359\u201363.","journal-title":"J Urol"},{"key":"5665_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00192-015-2839-x","volume":"27","author":"P Miotla","year":"2016","unstructured":"Miotla P, Futyma K, Cartwright R, et al. Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery. Int Urogynecol J. 2016;27:393\u20138.","journal-title":"Int Urogynecol J"},{"key":"5665_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/j.1742-1241.2011.02663.x","volume":"65","author":"C Dowson","year":"2011","unstructured":"Dowson C, Sahai A, Watkins J, Dasgupta P, Khan MS. The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. Int J Clin Pract. 2011;65:698\u2013704.","journal-title":"Int J Clin Pract"},{"key":"5665_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","volume":"61","author":"C Dowson","year":"2011","unstructured":"Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2011;61:834\u20139.","journal-title":"Eur Urol"},{"key":"5665_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/luts.12321","volume":"13","author":"AS El-Hefnawy","year":"2021","unstructured":"El-Hefnawy AS, Elbaset MA, Taha DE, et al. Trigonal-sparing versus trigonal-involved Botox injection for treatment of idiopathic overactive bladder: a randomized clinical trial. Low Urin Tract Symptoms. 2021;13:22\u201330.","journal-title":"Low Urin Tract Symptoms"},{"key":"5665_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.uroco.2015.10.010","volume":"27","author":"I Ospina-Galeano","year":"2018","unstructured":"Ospina-Galeano I, Medina-Polo J, Rosa-Kerhmann S, Villacampa F, Guerrero-Ramos F, Passas-Mart\u00ednez J. Use of onabotulinum toxin A in patients with idiopathic overactive bladder and a lack of efficacy, intolerance or contraindication with anticholinergics. Urol Colomb. 2018;27:86\u201391.","journal-title":"Urol Colomb"},{"key":"5665_CR26","first-page":"03","volume":"03","author":"NJ Kocher","year":"2022","unstructured":"Kocher NJ, Zillioux J, Goldman HB. Patient perceived improvement and medication resumption rates after intradetrusor onabotulinumtoxina for idiopathic urgency urinary incontinence. Int Urogynecol J. 2022;03:03.","journal-title":"Int Urogynecol J"},{"key":"5665_CR27","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","volume":"177","author":"A Sahai","year":"2007","unstructured":"Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231\u20136.","journal-title":"J Urol"},{"key":"5665_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","volume":"176","author":"DM Schmid","year":"2006","unstructured":"Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177\u201385.","journal-title":"J Urol"},{"key":"5665_CR29","first-page":"8838","volume":"24","author":"H Sherif","year":"2017","unstructured":"Sherif H, Khalil M, Omar R. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation. Can J Urol. 2017;24:8838\u201346.","journal-title":"Can J Urol"},{"key":"5665_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sc.2012.180","volume":"51","author":"C Jia","year":"2013","unstructured":"Jia C, Liao LM, Chen G, Sui Y. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord. 2013;51:487\u201390.","journal-title":"Spinal Cord"},{"key":"5665_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ana.21209","volume":"62","author":"V Kalsi","year":"2007","unstructured":"Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62:452\u20137.","journal-title":"Ann Neurol"},{"key":"5665_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.23736\/S2724-6051.21.04227-2","volume":"74","author":"A Giannantoni","year":"2022","unstructured":"Giannantoni A, Gubbiotti M, Rubilotta E, Balzarro M, Antonelli A, Bini V. IncobotulinumtoxinA versus onabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial. Minerva Urol Nephrol. 2022;74:625\u201335.","journal-title":"Minerva Urol Nephrol"},{"key":"5665_CR33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.eururo.2007.08.039","volume":"53","author":"X Gam\u00e9","year":"2008","unstructured":"Gam\u00e9 X, Castel-Lacanal E, Bentaleb Y, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53:613\u20138.","journal-title":"Eur Urol"},{"key":"5665_CR34","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.juro.2010.12.002","volume":"185","author":"S Khan","year":"2011","unstructured":"Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185:1344\u20139.","journal-title":"J Urol"},{"key":"5665_CR35","doi-asserted-by":"publisher","first-page":"33197","DOI":"10.1038\/srep33197","volume":"6","author":"L Leitner","year":"2016","unstructured":"Leitner L, Sammer U, Walter M, et al. Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep. 2016;6:33197.","journal-title":"Sci Rep"},{"key":"5665_CR36","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/nau.24519","volume":"39","author":"ESR Pereira","year":"2020","unstructured":"Pereira ESR, Ponte C, Lopes F, Palma Dos Reis J. Alkalinized lidocaine solution as a first-line local anesthesia protocol for intradetrusor injection of onabotulinum toxin A: results from a double-blinded randomized controlled trial. Neurourol Urodyn. 2020;39:2471\u20139.","journal-title":"Neurourol Urodyn"},{"key":"5665_CR37","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","volume":"174","author":"R Popat","year":"2005","unstructured":"Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005;174:984\u20139.","journal-title":"J Urol"},{"key":"5665_CR38","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.21037\/tau-21-62","volume":"10","author":"C Jia","year":"2021","unstructured":"Jia C, Xing T, Shang Z, Cui X, Wang Q, Ou T. Botulinum toxin A improves neurogenic bladder fibrosis by suppressing transforming growth factor \u00df1 expression in rats. Transl Androl Urol. 2021;10:2000\u20137.","journal-title":"Transl Androl Urol"},{"issue":"Suppl 1","key":"5665_CR39","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/S0302-2838(21)00417-6","volume":"79","author":"AG Giannantoni","year":"2021","unstructured":"Giannantoni AG, Gubbiotti M, Rubilotta E, Balzarro M, Antonelli A, Bini V. IncobotulinumtoxinA is not inferior to OnabotulinumtoxinA intradetrusor injections in the treatment of neurogenic detrusor overactivity incontinence: a multicentre, randomized, double-blind, clinical trial. Eur Urol. 2021;79(Suppl 1):S30\u20131.","journal-title":"Eur Urol"},{"key":"5665_CR40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.juro.2018.03.132","volume":"200","author":"AW Stamm","year":"2018","unstructured":"Stamm AW, Adelstein SA, Chen A, Lucioni A, Kobashi KC, Lee UJ. Inconsistency in the definition of urinary tract infection after intravesical botulinum toxin A injection: a systematic review. J Urol. 2018;200:809\u201314.","journal-title":"J Urol"},{"key":"5665_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/nau.22598","volume":"34","author":"Y Cui","year":"2015","unstructured":"Cui Y, Zhou X, Zong H, Yan H, Zhang Y. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis. Neurourol Urodyn. 2015;34:413\u20139.","journal-title":"Neurourol Urodyn"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05665-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-023-05665-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-023-05665-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T14:24:32Z","timestamp":1706192672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-023-05665-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5665"],"URL":"https:\/\/doi.org\/10.1007\/s00192-023-05665-4","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}